GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Short Percentage of Float

SynAct Pharma AB (OSTO:SYNACT) Short Percentage of Float


View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of SynAct Pharma AB's Short Percentage of Float

For the Biotechnology subindustry, SynAct Pharma AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SynAct Pharma AB's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's Short Percentage of Float falls into.


SynAct Pharma AB (OSTO:SYNACT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Short Percentage of Float
Comparable Companies
XSAT:CURAS OSTO:XBRANE OSTO:CANTA OSTO:ITECH OSTO:DMYD B OSTO:INIT OSTO:ONCO OSTO:IVACC OSTO:INDEX OSTO:KDEV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
8F8:Germany
Address
Sheelevagen 2, Lund, SWE, 223 81
Website
https://www.synactpharma.se
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines